ISO 9001 : 2008 CERTIFICATION AWARDED

9th March 2009

Proteome Sciences plc is pleased to announce that it has received ISO 9001:2008 certification from the German Society for Certification of Management Systems for its facilities in Frankfurt, Germany. This certification covers Proteome Sciences' biomarker activities, rapid assay development, chemical and peptide synthesis and isobaric tagging development and production.

The Frankfurt facility was specifically designed to deliver a growing product line of isobaric Tandem Mass Tags® (TMT®) for quantitative mass spectrometry and to undertake biomarker programmes for customers.

Proteome Sciences now provides a comprehensive range of contract biomarker services under ISO 9001: 2008 for discovery and validation of protein and peptide biomarkers, for rapid development of mass spectrometry based assays and for the measurement of protein and peptide drugs and their metabolites in pharmacokinetics.

The ISO 9001:2008 certification is an important milestone for the company in supporting the global marketing strategy through the expansion of its high quality services and products based on the proprietary isobaric Tandem Mass Tag® technology and from PS Biomarker Services™ available through the ProteoSHOP® platform.

Christopher Pearce, Chief Executive Officer of Proteome Sciences, commented:

"We have made a considerable investment in time and effort to establish the highest international standard of quality management systems into our biomarker services and we are delighted to be one of the first companies globally to be awarded ISO 9001:2008 accreditation. This further underpins our compelling TMT® isobaric tagging products and allows us to more comprehensively exploit the fast growing field of biomarker qualification and mass spectrometry assays through the provision of ISO certified biomarker services for our customers.

It is highly opportune timing to obtain the ISO 9001:2008 standard, with isobaric Tandem Mass Tag® technology at the point where pharmaceutical developers can use biomarkers as part of the drug development decision-making process and when global regulators require increasing biomarker data to support drug approval.

Biomarkers are increasingly a key part of early disease detection, drug development and disease management and our expertise addresses all of these applications."